Metabolic Syndrome in Children and Adolescents: Looking to New Markers
Metabolic syndrome (MetS) was first defined by Reaven, but its diagnostic criteria are controversial, particularly in children and adolescents. MetS is a common health problem globally, and many studies revealed its association with diabetes and cardiovascular diseases, and hence an agreed definitio...
Gespeichert in:
Veröffentlicht in: | Current treatment options in pediatrics 2021-09, Vol.7 (3), p.152-166 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 166 |
---|---|
container_issue | 3 |
container_start_page | 152 |
container_title | Current treatment options in pediatrics |
container_volume | 7 |
creator | Fazeli, Mostafa Mohammad-Zadeh, Mohammad Meshkat, Zahra Ghazizadeh, Hamideh Barati, Elham Ferns, Gordon A Ghayour-Mobarhan, Majid |
description | Metabolic syndrome (MetS) was first defined by Reaven, but its diagnostic criteria are controversial, particularly in children and adolescents. MetS is a common health problem globally, and many studies revealed its association with diabetes and cardiovascular diseases, and hence an agreed definition would be useful. To date, many attempts have been performed to achieve consensus and a more accurate definition by investigating new criteria, and introducing new markers and cutoff values. The prevalence of MetS varies greatly, in part due to the application of these different criteria. This variation in definition makes it difficult for public health professionals to accurately identify and manage MetS in pediatrics. New components in defining MetS, such as hyperuricemia, have been added to the standard criteria. An attempt has also been made to identify reliable biomarkers for the identification of MetS, but these have been inconsistent. Even for standard components including obesity, new cutoff criteria that have been adopted for different ethnicities, and gender, the search for a better understanding of MetS is continuing especially in pediatrics. |
doi_str_mv | 10.1007/s40746-021-00226-7 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2933778042</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2933778042</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1857-ae4eb11b0ec43b66a6d93f8a02a9b8e37e8b323568027819a3c79f346c273b343</originalsourceid><addsrcrecordid>eNp9kLFOwzAQhi0EElXpCzBZYg6c7dR22KqIAlILAzBbTnIpaVO72KlQ357QIMHEcnfD9_8nfYRcMrhmAOompqBSmQBnCQDnMlEnZMRZphMJWp_-uc_JJMY1ADB1HCMyX2JnC982JX05uCr4LdLG0fy9aauAjlpX0VnlW4wlui7e0oX3m8ataOfpE37SpQ0bDPGCnNW2jTj52WPyNr97zR-SxfP9Yz5bJCXTU5VYTLFgrAAsU1FIaWWViVpb4DYrNAqFuhBcTKUGrjTLrChVVotUllyJQqRiTK6G3l3wH3uMnVn7fXD9S8MzIZTSkPKe4gNVBh9jwNrsQrO14WAYmG9lZlBmemXmqMyoPiSGUOxht8LwW_1P6gusTWx8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2933778042</pqid></control><display><type>article</type><title>Metabolic Syndrome in Children and Adolescents: Looking to New Markers</title><source>ProQuest Central (Alumni Edition)</source><source>ProQuest Central UK/Ireland</source><source>SpringerLink Journals - AutoHoldings</source><source>ProQuest Central</source><creator>Fazeli, Mostafa ; Mohammad-Zadeh, Mohammad ; Meshkat, Zahra ; Ghazizadeh, Hamideh ; Barati, Elham ; Ferns, Gordon A ; Ghayour-Mobarhan, Majid</creator><creatorcontrib>Fazeli, Mostafa ; Mohammad-Zadeh, Mohammad ; Meshkat, Zahra ; Ghazizadeh, Hamideh ; Barati, Elham ; Ferns, Gordon A ; Ghayour-Mobarhan, Majid</creatorcontrib><description>Metabolic syndrome (MetS) was first defined by Reaven, but its diagnostic criteria are controversial, particularly in children and adolescents. MetS is a common health problem globally, and many studies revealed its association with diabetes and cardiovascular diseases, and hence an agreed definition would be useful. To date, many attempts have been performed to achieve consensus and a more accurate definition by investigating new criteria, and introducing new markers and cutoff values. The prevalence of MetS varies greatly, in part due to the application of these different criteria. This variation in definition makes it difficult for public health professionals to accurately identify and manage MetS in pediatrics. New components in defining MetS, such as hyperuricemia, have been added to the standard criteria. An attempt has also been made to identify reliable biomarkers for the identification of MetS, but these have been inconsistent. Even for standard components including obesity, new cutoff criteria that have been adopted for different ethnicities, and gender, the search for a better understanding of MetS is continuing especially in pediatrics.</description><identifier>ISSN: 2198-6088</identifier><identifier>EISSN: 2198-6088</identifier><identifier>DOI: 10.1007/s40746-021-00226-7</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Biomarkers ; Cardiovascular disease ; Critical Care Medicine ; Family Medicine ; General Practice ; Hot Topic ; Insulin resistance ; Intensive ; Maternal and Child Health ; Medicine ; Medicine & Public Health ; Pediatrics ; Sleep apnea</subject><ispartof>Current treatment options in pediatrics, 2021-09, Vol.7 (3), p.152-166</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021</rights><rights>The Author(s), under exclusive licence to Springer Nature Switzerland AG 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1857-ae4eb11b0ec43b66a6d93f8a02a9b8e37e8b323568027819a3c79f346c273b343</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40746-021-00226-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2933778042?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,21388,21389,27924,27925,33530,33744,41488,42557,43659,43805,51319,64385,64389,72469</link.rule.ids></links><search><creatorcontrib>Fazeli, Mostafa</creatorcontrib><creatorcontrib>Mohammad-Zadeh, Mohammad</creatorcontrib><creatorcontrib>Meshkat, Zahra</creatorcontrib><creatorcontrib>Ghazizadeh, Hamideh</creatorcontrib><creatorcontrib>Barati, Elham</creatorcontrib><creatorcontrib>Ferns, Gordon A</creatorcontrib><creatorcontrib>Ghayour-Mobarhan, Majid</creatorcontrib><title>Metabolic Syndrome in Children and Adolescents: Looking to New Markers</title><title>Current treatment options in pediatrics</title><addtitle>Curr Treat Options Peds</addtitle><description>Metabolic syndrome (MetS) was first defined by Reaven, but its diagnostic criteria are controversial, particularly in children and adolescents. MetS is a common health problem globally, and many studies revealed its association with diabetes and cardiovascular diseases, and hence an agreed definition would be useful. To date, many attempts have been performed to achieve consensus and a more accurate definition by investigating new criteria, and introducing new markers and cutoff values. The prevalence of MetS varies greatly, in part due to the application of these different criteria. This variation in definition makes it difficult for public health professionals to accurately identify and manage MetS in pediatrics. New components in defining MetS, such as hyperuricemia, have been added to the standard criteria. An attempt has also been made to identify reliable biomarkers for the identification of MetS, but these have been inconsistent. Even for standard components including obesity, new cutoff criteria that have been adopted for different ethnicities, and gender, the search for a better understanding of MetS is continuing especially in pediatrics.</description><subject>Biomarkers</subject><subject>Cardiovascular disease</subject><subject>Critical Care Medicine</subject><subject>Family Medicine</subject><subject>General Practice</subject><subject>Hot Topic</subject><subject>Insulin resistance</subject><subject>Intensive</subject><subject>Maternal and Child Health</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Pediatrics</subject><subject>Sleep apnea</subject><issn>2198-6088</issn><issn>2198-6088</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kLFOwzAQhi0EElXpCzBZYg6c7dR22KqIAlILAzBbTnIpaVO72KlQ357QIMHEcnfD9_8nfYRcMrhmAOompqBSmQBnCQDnMlEnZMRZphMJWp_-uc_JJMY1ADB1HCMyX2JnC982JX05uCr4LdLG0fy9aauAjlpX0VnlW4wlui7e0oX3m8ataOfpE37SpQ0bDPGCnNW2jTj52WPyNr97zR-SxfP9Yz5bJCXTU5VYTLFgrAAsU1FIaWWViVpb4DYrNAqFuhBcTKUGrjTLrChVVotUllyJQqRiTK6G3l3wH3uMnVn7fXD9S8MzIZTSkPKe4gNVBh9jwNrsQrO14WAYmG9lZlBmemXmqMyoPiSGUOxht8LwW_1P6gusTWx8</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>Fazeli, Mostafa</creator><creator>Mohammad-Zadeh, Mohammad</creator><creator>Meshkat, Zahra</creator><creator>Ghazizadeh, Hamideh</creator><creator>Barati, Elham</creator><creator>Ferns, Gordon A</creator><creator>Ghayour-Mobarhan, Majid</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20210901</creationdate><title>Metabolic Syndrome in Children and Adolescents: Looking to New Markers</title><author>Fazeli, Mostafa ; Mohammad-Zadeh, Mohammad ; Meshkat, Zahra ; Ghazizadeh, Hamideh ; Barati, Elham ; Ferns, Gordon A ; Ghayour-Mobarhan, Majid</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1857-ae4eb11b0ec43b66a6d93f8a02a9b8e37e8b323568027819a3c79f346c273b343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biomarkers</topic><topic>Cardiovascular disease</topic><topic>Critical Care Medicine</topic><topic>Family Medicine</topic><topic>General Practice</topic><topic>Hot Topic</topic><topic>Insulin resistance</topic><topic>Intensive</topic><topic>Maternal and Child Health</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Pediatrics</topic><topic>Sleep apnea</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fazeli, Mostafa</creatorcontrib><creatorcontrib>Mohammad-Zadeh, Mohammad</creatorcontrib><creatorcontrib>Meshkat, Zahra</creatorcontrib><creatorcontrib>Ghazizadeh, Hamideh</creatorcontrib><creatorcontrib>Barati, Elham</creatorcontrib><creatorcontrib>Ferns, Gordon A</creatorcontrib><creatorcontrib>Ghayour-Mobarhan, Majid</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Current treatment options in pediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fazeli, Mostafa</au><au>Mohammad-Zadeh, Mohammad</au><au>Meshkat, Zahra</au><au>Ghazizadeh, Hamideh</au><au>Barati, Elham</au><au>Ferns, Gordon A</au><au>Ghayour-Mobarhan, Majid</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metabolic Syndrome in Children and Adolescents: Looking to New Markers</atitle><jtitle>Current treatment options in pediatrics</jtitle><stitle>Curr Treat Options Peds</stitle><date>2021-09-01</date><risdate>2021</risdate><volume>7</volume><issue>3</issue><spage>152</spage><epage>166</epage><pages>152-166</pages><issn>2198-6088</issn><eissn>2198-6088</eissn><abstract>Metabolic syndrome (MetS) was first defined by Reaven, but its diagnostic criteria are controversial, particularly in children and adolescents. MetS is a common health problem globally, and many studies revealed its association with diabetes and cardiovascular diseases, and hence an agreed definition would be useful. To date, many attempts have been performed to achieve consensus and a more accurate definition by investigating new criteria, and introducing new markers and cutoff values. The prevalence of MetS varies greatly, in part due to the application of these different criteria. This variation in definition makes it difficult for public health professionals to accurately identify and manage MetS in pediatrics. New components in defining MetS, such as hyperuricemia, have been added to the standard criteria. An attempt has also been made to identify reliable biomarkers for the identification of MetS, but these have been inconsistent. Even for standard components including obesity, new cutoff criteria that have been adopted for different ethnicities, and gender, the search for a better understanding of MetS is continuing especially in pediatrics.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><doi>10.1007/s40746-021-00226-7</doi><tpages>15</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2198-6088 |
ispartof | Current treatment options in pediatrics, 2021-09, Vol.7 (3), p.152-166 |
issn | 2198-6088 2198-6088 |
language | eng |
recordid | cdi_proquest_journals_2933778042 |
source | ProQuest Central (Alumni Edition); ProQuest Central UK/Ireland; SpringerLink Journals - AutoHoldings; ProQuest Central |
subjects | Biomarkers Cardiovascular disease Critical Care Medicine Family Medicine General Practice Hot Topic Insulin resistance Intensive Maternal and Child Health Medicine Medicine & Public Health Pediatrics Sleep apnea |
title | Metabolic Syndrome in Children and Adolescents: Looking to New Markers |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T02%3A58%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metabolic%20Syndrome%20in%20Children%20and%20Adolescents:%20Looking%20to%20New%20Markers&rft.jtitle=Current%20treatment%20options%20in%20pediatrics&rft.au=Fazeli,%20Mostafa&rft.date=2021-09-01&rft.volume=7&rft.issue=3&rft.spage=152&rft.epage=166&rft.pages=152-166&rft.issn=2198-6088&rft.eissn=2198-6088&rft_id=info:doi/10.1007/s40746-021-00226-7&rft_dat=%3Cproquest_cross%3E2933778042%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2933778042&rft_id=info:pmid/&rfr_iscdi=true |